Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Ter Arkh ; 95(2): 120-129, 2023 Mar 30.
Artigo em Russo | MEDLINE | ID: mdl-37167127

RESUMO

BACKGROUND: First-line therapy does not always provide a high level of Helicobacter pylori eradication due to the increase of H. pylori resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical H. pylori furazolidone-containing regimens. MATERIALS AND METHODS: Adult H. pylori infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on H. pylori management (Hp-EuReg). Data were collected at AEG-REDCap e-CRF from 2013 to 2021 and the quality was reviewed. Modified intention-to-treat (mITT) effectiveness analyses were performed. RESULTS: Overall 106 patients received empirical furazolidone-containing therapy in Russia. Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9.4%). Treatment duration of 7 days was assigned to 2 (1.9%) patients, 10-day eradication therapy in case of 80 (75%) and 14 days - in 24 (23%) patients. Furazolidone was mainly used in first- (79%) and second-line (21%) regimens. The methods used to diagnose H. pylori infection were: histology (81%), stool antigen test (64%), 13C-urea breath test (6.6%), and rapid urease test (1.9%). The mITT effectiveness of sequential therapy was 100%; 93% with the triple therapy and 75.5% with quadruple therapy. Compliance was reported in 98% of cases. Adverse events were revealed in 5.7% of patients, mostly nausea (3.8%). No serious adverse events were reported. CONCLUSION: Furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.


Assuntos
Infecções por Helicobacter , Helicobacter pylori , Adulto , Humanos , Furazolidona/efeitos adversos , Estudos Prospectivos , Quimioterapia Combinada , Antibacterianos/efeitos adversos , Amoxicilina/efeitos adversos , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/epidemiologia , Infecções por Helicobacter/diagnóstico , Inibidores da Bomba de Prótons/efeitos adversos , Resultado do Tratamento , Federação Russa/epidemiologia , Sistema de Registros
2.
Ter Arkh ; 94(1): 48-56, 2022 Jan 15.
Artigo em Russo | MEDLINE | ID: mdl-36286919

RESUMO

BACKGROUND: Recently, there has been an increase in the prevalence of gastroesophageal reflux disease (GERD) in Northern Europe, North America and East Asia. However data on GERD prevalence in Russian population are very limited. AIM: To determine the prevalence of GERD among the population of Russia, the clinical spectrum of GERD symptoms, the main drugs used for GERD treatment, and the rate of their administration. MATERIALS AND METHODS: The study was conducted from November 2015 to January 2017 in 8 cities of Russia. A survey of patients over the age of 18 years old visiting outpatient medical institutions for any reason, including patients without gastrointestinal complaints was carried out using a short version of the Mayo Clinic questionnaire. RESULTS: In total, 6132 questionnaires of patients aged 1890 years were analyzed [2456 men (40.1%) and 3676 women (59.9%), mean age 46.615.4 years]. The GERD prevalence among the interviewed patients was 34.2%. The incidence of GERD increased depending on body mass index and the age of the patients. Medications used by the patients for heartburn relief included proton pump inhibitors 59.96%, antacids 67.92%, H2-histamine receptor blockers 11.42%, alginates 18.41% of patients. CONCLUSION: The results of this study indicate a high prevalence of GERD among residents of Russian cities applying for primary health care (34.2%). In comparison with previous studies, an increase in the proportion of GERD patients taking proton pump inhibitors was noted; in most cases the regimen of their intake was in accordance with the recommendations.


Assuntos
Antiácidos , Refluxo Gastroesofágico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antiácidos/uso terapêutico , Refluxo Gastroesofágico/tratamento farmacológico , Refluxo Gastroesofágico/epidemiologia , Refluxo Gastroesofágico/diagnóstico , Pacientes Ambulatoriais , Prevalência , Inibidores da Bomba de Prótons/uso terapêutico , Bombas de Próton/uso terapêutico , Receptores Histamínicos , Federação Russa/epidemiologia , Inquéritos e Questionários
3.
Ter Arkh ; 91(2): 16-24, 2019 Feb 15.
Artigo em Russo | MEDLINE | ID: mdl-32598623

RESUMO

The multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group (EHMSG) is conducted in 27 countries in Europe. The data from the Russian part of the European registry for the management of Helicobacter pylori infection (European Registry on the management of Helicobacter pylori infection, protocol: "Hp-EuReg") allows us to analyze the real clinical practice of diagnosis and treatment of H. pylori and compare it with international recommendations. MATERIALS AND METHODS: A comparative analysis of the data entered in the register by the Russian research centers "Hp-EuReg", in the period from 2013 to 2018, was conducted. RESULTS AND DISCUSSION: Invasive diagnostic methods prevail for the primary diagnosis of H. pylori [histology - 20.3% (in 2013 year) - 43.9% (in 2018 year), rapid urease test - 31.7% and 47.8% respectively]. The most popular mode of eradication therapy is a 10-day triple therapy (62.8-76.2%), the effectiveness of which does not exceed 79% (per protocol). Invasive tests (histology) are the leading method for control the effectiveness of therapy, however, there is a tendency towards a wider use of non-invasive methods (H. pylori stool antigen - from 17% in 2013 to 29.3% in 2018 and urea breath test from 6.9 to 18.3%, respectively). Serological test to control the effectiveness of eradication is still used from 8.2% (2013) to 6.1% (2018). Eradication therapy was not performed in 28% of patients throughout the entire observation period. CONCLUSION: In Russia, despite approved domestic and international recommendations, deviations in clinical practice persist, both during eradication therapy and in monitoring the effectiveness of eradication therapy.


Assuntos
Antibacterianos/uso terapêutico , Antiulcerosos/uso terapêutico , Antígenos de Bactérias/análise , Testes Respiratórios/métodos , Quimioterapia Combinada/métodos , Fezes/microbiologia , Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/isolamento & purificação , Antibacterianos/administração & dosagem , Antiulcerosos/administração & dosagem , Quimioterapia Combinada/efeitos adversos , Europa (Continente) , Infecções por Helicobacter/epidemiologia , Helicobacter pylori/imunologia , Humanos , Estudos Prospectivos , Sistema de Registros , Federação Russa/epidemiologia
4.
Ter Arkh ; 90(2): 35-42, 2018 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-30701770

RESUMO

AIM: European Registry on the management of Helicobacter pylori infection («Hp-EuReg¼) - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations. MATERIALS AND METHODS: The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg¼ in 2013-2017, who were underwent 1st line eradication therapy. RESULTS: The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. CONCLUSION: Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.


Assuntos
Antibacterianos , Infecções por Helicobacter , Inibidores da Bomba de Prótons , Amoxicilina/uso terapêutico , Antibacterianos/uso terapêutico , Claritromicina , Quimioterapia Combinada , Europa (Continente) , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Humanos , Estudos Prospectivos , Inibidores da Bomba de Prótons/uso terapêutico , Sistema de Registros
5.
Eksp Klin Gastroenterol ; (2): 30-4, 2016.
Artigo em Russo | MEDLINE | ID: mdl-27301114

RESUMO

INTRODUCTION: Helicobacter pylori infection is due to the high prevalence in population attracts the clinical interest of researchers in the whole World. It is well known that this microorganism not only resides in the mucosa of the gastrointestinal tract, but is also defined in the periodontal pocket of the oral cavity. THE AIM OF INVESTIGATION: to evaluate Helicobacter pylori diagnostics in the mouth and prove a method of relief of the inflammatory process by applying immunomodulator Imudon. RESULTS. On the basis of obtained results it was found that the inclusion of topical immunomodulator Imudon in the complex therapy of Helicobacter pylori-associated diseases leads to reduction of inflammatory potential through the decrease of the TNFα, IL-6 activity in saliva and to increase the protective properties of saliva as a result of increased levels of mucin, significantly reduces the frequency of relapses in the one year after therapy. CONCLUSION: It is practically important to determine the effectiveness of eradication therapy by the study of the contents of the tooth-gingival pocket for the detection of genetic material of Helicobacter pylori, as well as to include in the complex therapy of Helicobacter pylori-associated diseases of the immune modulator Imudon.


Assuntos
Antígenos de Bactérias/uso terapêutico , Antígenos de Fungos/uso terapêutico , Úlcera Duodenal/imunologia , Infecções por Helicobacter/imunologia , Helicobacter pylori/efeitos dos fármacos , Imunidade nas Mucosas/efeitos dos fármacos , Saliva/metabolismo , Timerosal/uso terapêutico , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Antígenos de Bactérias/administração & dosagem , Antígenos de Fungos/administração & dosagem , Combinação de Medicamentos , Quimioterapia Combinada , Úlcera Duodenal/tratamento farmacológico , Úlcera Duodenal/microbiologia , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/microbiologia , Helicobacter pylori/isolamento & purificação , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Humoral/efeitos dos fármacos , Interleucina-6/imunologia , Interleucina-6/metabolismo , Masculino , Saliva/imunologia , Timerosal/administração & dosagem , Resultado do Tratamento , Fator de Necrose Tumoral alfa/imunologia , Fator de Necrose Tumoral alfa/metabolismo
6.
Eksp Klin Gastroenterol ; (5): 22-27, 2016.
Artigo em Russo | MEDLINE | ID: mdl-28614641

RESUMO

RELEVANCE: Currently, there is a need to study the genetic diversity of H.pylori in patients with variety of acid-related dis- eases to develop new strategies for the treatment of patients with H.pylori to predict high efficiency of treatment. OBJECTIVE: To assess the effectiveness of schemes of eradication therapy in patients with chronic pancreatitis and concom- itant H.pylori infection. MATERIALS AND METHODS: The study included 108 patients with H.pylori infection: 63 patients had chronic pancreatitis and were concomitant with H.pylori-infection and 45 patients were without chronic pancreatitis and had H.pylori infection with a chronic gastritis. All patients were determined by factors of pathogenicity of H.pylori by immunoblotting. After forming the group randomized patients received eradication therapy scheme I and the scheme I with inclusion of bismuth tripotassium dicitrate. CONCLUSIONS: The effectiveness of H.pylori eradication therapy is dependent on the genetic component of H.pylori. In the presence of H.pylori pathogenicity factors p33, p30, p26, p19, p17 in order to increase the effectiveness of treatment the scheme of eradication therapy I line drugs bismuth tri dicitrate should be included.


Assuntos
Antibacterianos/uso terapêutico , Antiulcerosos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Compostos Organometálicos/uso terapêutico , Pancreatite Crônica/tratamento farmacológico , Amoxicilina/administração & dosagem , Amoxicilina/uso terapêutico , Antibacterianos/administração & dosagem , Antiulcerosos/administração & dosagem , Claritromicina/administração & dosagem , Claritromicina/uso terapêutico , Quimioterapia Combinada , Infecções por Helicobacter/complicações , Infecções por Helicobacter/microbiologia , Helicobacter pylori/efeitos dos fármacos , Helicobacter pylori/genética , Helicobacter pylori/patogenicidade , Humanos , Compostos Organometálicos/administração & dosagem , Pancreatite Crônica/complicações , Pancreatite Crônica/microbiologia , Rabeprazol/administração & dosagem , Rabeprazol/uso terapêutico , Resultado do Tratamento , Virulência , Fatores de Virulência/genética
8.
Eksp Klin Gastroenterol ; (11): 8-13, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25842656

RESUMO

THE PURPOSE OF THE STUDY: To study the genetic diversity of H. pylori in patients with chronic gastritis, peptic ulcer disease, chronic pancreatitis. MATERIALS AND METHODS: The study involved 490 patients with gastric ulcer, duodenal ulcer, chronic superficial gastritis, chronic atrophic gastritis, chronic pancreatitis. Diagnosis of H. pylori infection was carried out by the following methods: morphological, urea breath test serological (determining the concentration of IgG antibodies to H. pylori and immunoblotting) and by polymerase chain reaction. For genotyping of H. pylori using sets of primers with a mixture of CagA, VacA s1/ s2, VacA m1, VacA m2, IceA1, IceA2, BabA. To perform immunoblotting using Anti-Helicobacter pylori EUROLINE-Western blot (IgG), based on the Western blot method using test strips with antigens separated by electrophoresis cell extract H. pylori. Statistical computer processing was performed using software packages Statistic for Windows 6.0. RESULTS: The virulent genotype of H. pylori was determined in 92% cases of duodenal ulcer. In chronic non-atrophic and atrophic gastritis virulent genotypes of H. pylori were not detected. In case of uncomplicated duodenal ulcer we revealed isolated (vacA m2) and combined (vacA s1/ s2) genotypes of H.pylori in 23% of cases, of them monogenotip VacAm2 (vacuolating-associated cytotoxin) was determined in 83%. In complicated duodenal ulcer the combined genotype of H. pylori (vacAs1/ s2; vacAs1/ s2 + vacAm1 + vacAm2; vacAs1/ s2 + vacAm2) and mixed genotype of H. pylori (vacAs1/ s2 + cagA, vacAs1/ s2 + iceA2, vacAm1 + cagA + iceA2) were determined in 77% of the samples. In cases of chronic pancreatitis the vacuolating cytotoxin VacA was detected in 35.7%, such as in the control group it was 81.8%. Genes encoding the production of urease (subunit A) were found in 85.7% of chronic pancreatitis patients, in the control group--54.5%. Genes encoding the synthesis of outer membrane proteins of H. pylori such as p26, p19, p17 were detected in 82.1% of patients with chronic pancreatitis, in patients of the control group--54.5%. H. pylori outer membrane proteins with molecular weights of 30 and 33kDa (p30 and p33) were detected in 85.7% of patients with chronic pancreatitis. CONCLUSION: The bacterium H. pylori, which is the main cause of acid diseases, realizes effect through its pathogenicity factors. Waste products of H. pylori have a direct damaging effect on the mucous membrane of the stomach and duodenum, contributing to the release of lysosomal enzymes, a number of cytokines. They are cause the development of inflammatory processes in the mucosa. Lipopolysaccharide of outer membrane of H. pylori cause immune response of the human body and the development of chronic inflammation at the system level. Set of pathogenicity factors of H. pylori determine the nature and severity of the pathological processes triggered by the bacterium at different levels of the microorganism.


Assuntos
Ácido Gástrico/metabolismo , Gastrite/microbiologia , Variação Genética , Infecções por Helicobacter/microbiologia , Helicobacter pylori/genética , Pancreatite Crônica/microbiologia , Úlcera Péptica/microbiologia , Estudos de Casos e Controles , Mucosa Gástrica/metabolismo , Mucosa Gástrica/microbiologia , Gastrite/metabolismo , Técnicas de Genotipagem , Infecções por Helicobacter/metabolismo , Helicobacter pylori/isolamento & purificação , Helicobacter pylori/patogenicidade , Humanos , Pancreatite Crônica/metabolismo , Úlcera Péptica/metabolismo , Virulência/genética
9.
Eksp Klin Gastroenterol ; (11): 14-8, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25842657

RESUMO

RESEARCH OBJECTIVE: To study the psycho-emotional status and prevalence of the coronary heart disease (CHD) and the idiopathic hypertensia (IH) at patients with the peptic ulcer of a stomach (PUS) and at patients with a peptic ulcer of a duodenum is (YaB DPK). MATERIALS AND METHODS: Examination of 226 patients with an exacerbation of a peptic ulcer was conducted. Patients were distributed in 3 groups of observation depending on localization of ulcerative process. At all surveyed questioning was carried out, data on heriditary burdeness, smoking, alcohol intake, existence of somatopathies were specified, clinic-morphological implications of a peptic ulcer were studied. RESULTS: Feeling of alarm was present at 109 (48.2%) patients with a peptic ulcer, from them at 92 (40.7%) the subclinical level of alarm is noted, and at 17 (7.5%) clinically expressed form is taped. At 39.3% of the examined patients the depression is defined, from them two thirds of patients had the subclinical level of a depression, and 13 people suffered from clinically expressed depression form. Communication of recurrence with a stress was noted at 86.0% of patients, professionally caused stress--at 44.4%. In our research at the time of the beginning of a disease prevalence of an ischemic heart disease among patients with an ulcer of a duodenum (DPK) made 18.2%. In group of patients with the combined localization of ulcerative defect in a stomach and in DPK which already had an ischemic heart disease before emergence of the second ulcerative defect there were 26.6% that statistically significantly doesn't differ. However that by the time of emergence of the combined lesion this category of patients made already 73.4% is indicative. In case of DPK ulcer prevalence of an ischemic heart disease increased from the moment of the beginning of a disease until carrying out research twice (to 36.4%), but patients with the combined ultserozny lesion nevertheless distinguished both larger initial prevalence of an ischemic heart disease, and more expressed its gain. At the time of the beginning of a disease of GB met in a group of persons with the isolated ulcerative defect authentically more often (36.4% against 18.7% in group of patients with the combined localization of an ulcer). At the time of carrying out research prevalence of GB among patients with DPK ulcer (47.7%) whereas in group of the combined lesion of a stomach and DPK of GB without ischemic heart disease there was only every fourth patient remained significant by 2,7 times (DI 1.2-6.3). The combination of associated diseases of an ischemic heart disease and GB at patients with the advent of an ulcer at the same time in a stomach and DPK practically always met at the persons abusing alcohol and tobacco smoking that in general enlarges risk of development of an ulcer of the second localization by 7,6 times CONCLUSION: At the peptic ulcer (PU) of any localization the previous stress conducting quite often to formation of alarm and a depression conducts to also education a stress--the induced conditions, for example, of an arterial hypertonia, and later--to an ischemic heart disease. As specific to every second patient with the combined form of a peptic ulcer of a stomach and a duodenum it is possible to consider a polisintropiya from such the comorbidity diseases as coronary heart disease and an idiopathic hypertensia. The combination of these associated diseases to alcohol intake and tobacco smoking progressively enlarges risk of development of a peptic ulcer of the combined localization by 7,6 times in comparison with the isolated duodenum canker. RESEARCH OBJECTIVE: To define influence of the comorbidity diseases and risk.


Assuntos
Adaptação Psicológica , Úlcera Duodenal/psicologia , Hipertensão/psicologia , Isquemia Miocárdica/psicologia , Úlcera Gástrica/psicologia , Estresse Psicológico/psicologia , Adolescente , Adulto , Idoso , Ansiedade/epidemiologia , Ansiedade/etiologia , Ansiedade/psicologia , Estudos de Casos e Controles , Depressão/epidemiologia , Depressão/etiologia , Depressão/psicologia , Úlcera Duodenal/complicações , Úlcera Duodenal/epidemiologia , Feminino , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/complicações , Isquemia Miocárdica/epidemiologia , Úlcera Gástrica/complicações , Úlcera Gástrica/epidemiologia , Estresse Psicológico/epidemiologia , Estresse Psicológico/etiologia , Adulto Jovem
10.
Eksp Klin Gastroenterol ; (8): 28-33, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24933945

RESUMO

UNLABELLED: The aim of this study was to evaluate the presence or absence of a relationship between the variants of the course of IBS and their association with genetic polymorphisms of genes and intergenic interaction of cytokines. MATERIALS AND METHODS: The sample consisted of 81 patients, the diagnosis was verified according to the criteria of the Rome III, were isolated psychopathological, morphological complications, extra-intestinal symptoms. Polymorphism genotyping IL-1Ra, IL-b, IL-4, TNFa performed by PCR. Statistical treatment are a non-parametric analysis of multiple comparisons, hierarchical log-linear analysis. It is found out the relation between the clinical variants with morphological changes of the mucous membrane of the large intestine, the association between gender characteristics of patients with IBS is established and with genetic polymorphisms of cytokines.


Assuntos
Proteína Antagonista do Receptor de Interleucina 1/genética , Interleucina-1beta/genética , Interleucina-4/genética , Mucosa Intestinal/patologia , Intestino Grosso/patologia , Síndrome do Intestino Irritável , Polimorfismo Genético , Fator de Necrose Tumoral alfa/genética , Adulto , Feminino , Humanos , Síndrome do Intestino Irritável/genética , Síndrome do Intestino Irritável/patologia , Masculino , Estudos Retrospectivos
11.
Eksp Klin Gastroenterol ; (8): 34-40, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24933946

RESUMO

RESEARCH OBJECTIVE: To define influence of the comorbidity diseases and risk factors of development of the combined peptic ulcer of a stomach and duodenum. MATERIALS AND METHODS: As a result of carried-out poll and inspection 250 patients with an exacerbation of a peptic ulcer were surveyed. Patients were distributed in 3 groups of observation depending on localization of ulcerative process. At all surveyed questioning was carried out, data on hereditary load, smoking, alcohol intake, existence of somatopathies were specified, clinic-morphological implications of a peptic ulcer were studied. RESULTS: The peptic ulcer of a stomach is characteristic for women (72.1%) and develops mainly aged from 45 till 59 years (60.3%). Peptic ulcer of duodenum men (76.3%) suffer mainly, the debut is the share in most cases of age from 18 to 44 years (79.1%). The combined canker of a stomach and duodenum meets at males (61.2%) more often, is initially involved in process ulcerogenesis by duodenum generally aged from 30 till 44 years (64.2%), accession of a canker of a stomach happens is delayed (at 38.8% within 16 and more years). In the analysis of risk factors at patients with the combined peptic ulcer of a stomach and duodenum depending on existence or absence specific to this category of patients of a background from such comorbidity diseases as IBS, HOBL and widespread osteochondrosis taped that larger prevalence of smoking (100%) and as the use (50%) and the excessive use (50%), alcohol are characteristic for the patients having a high comorbidity (a combination of three above nosologies). CONCLUSION: The greatest interest in respect of possible communication with formation of the combined peptic ulcer of a stomach and duodenum is represented by IBS, HOBL and osteochondrosis. And major factors of risk were smoking, the excessive alcohol intake, the burdened heredity.


Assuntos
Úlcera Duodenal/epidemiologia , Úlcera Duodenal/etiologia , Úlcera Gástrica/epidemiologia , Úlcera Gástrica/etiologia , Adulto , Fatores Etários , Úlcera Duodenal/patologia , Úlcera Duodenal/fisiopatologia , Duodeno/patologia , Duodeno/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Fatores Sexuais , Estômago/patologia , Estômago/fisiopatologia , Úlcera Gástrica/patologia , Úlcera Gástrica/fisiopatologia
13.
Artigo em Russo | MEDLINE | ID: mdl-16438383

RESUMO

The presence of genetic markers of vacA-positive strains with s1/s2 subtype (76%) with a high proportions (84%) of mixed genotype and detection in a breath air the ammonia at significantly high concentrations, have been found to be the specific features of H. pylori infection in patients with a severe course of duodenal ulcer. A low level of specific IgG antibodies, the growth of immunological inflammation markers and the depression of humoral immunity have been established.


Assuntos
Anticorpos Antibacterianos/sangue , Úlcera Duodenal , Infecções por Helicobacter , Helicobacter pylori/genética , Helicobacter pylori/imunologia , Imunoglobulina G/sangue , Amônia/análise , Amônia/metabolismo , Proteínas de Bactérias/genética , Testes Respiratórios , Úlcera Duodenal/sangue , Úlcera Duodenal/metabolismo , Úlcera Duodenal/microbiologia , Marcadores Genéticos , Infecções por Helicobacter/sangue , Infecções por Helicobacter/metabolismo , Infecções por Helicobacter/microbiologia , Helicobacter pylori/patogenicidade , Humanos , Polimorfismo Genético , Especificidade da Espécie , Virulência , Fatores de Virulência/genética
14.
Eksp Klin Gastroenterol ; (5): 15-20, 146, 2004.
Artigo em Russo | MEDLINE | ID: mdl-15770855

RESUMO

The role of ulceration risk factors in the development of duodenal ulcer complications was under examination. The leading role of risk factors for the development of complications in case of an infection of the stomach mucous coat with virulent VacA-positive strains of Helicobacter pylori belonging to the s1/s2 subtype and characterized by a high amount of mixed genotypes of the VacA gene (64%)--was established. The proved growth of immunological inflammation markers and depression of the humoral immunity part was discovered.


Assuntos
Úlcera Duodenal/complicações , Hemorragia Gastrointestinal/etiologia , Infecções por Helicobacter/complicações , Helicobacter pylori , Adulto , Formação de Anticorpos , Úlcera Duodenal/imunologia , Úlcera Duodenal/microbiologia , Hemorragia Gastrointestinal/microbiologia , Genótipo , Infecções por Helicobacter/imunologia , Helicobacter pylori/genética , Helicobacter pylori/isolamento & purificação , Helicobacter pylori/patogenicidade , Humanos , Imunidade Celular , Masculino , Pessoa de Meia-Idade , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...